

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Guilherme L. INDIG

Serial No.: 09/753,472

Docket No.: 032026:0667

Filed: January 3, 2001

Group Art Unit: 1614

For: **USE OF CRYSTAL VIOLET AS PHOTOCHEMOTHERAPEUTIC AGENT**

**DECLARATION UNDER 37 C.F.R. § 1.132 OF GUILHERME L. INDIG**

Box Non-Fee Amendment  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, Guilherme L. Indig, state and declare that:

1. I am an Assistant Professor of Pharmacy at the University of Wisconsin-Madison, located in Madison, Wisconsin.
2. I am one of six authors of the paper entitled "EFFECT OF MOLECULAR STRUCTURE ON THE PERFORMANCE OF TRIARYLMETHANE DYES AS THERAPEUTIC AGENTS FOR PHOTOCHEMICAL PURGING OF AUTOLOGOUS BONE MARROW GRAFTS FROM RESIDUAL TUMOR CELLS," published in the Journal of Pharmaceutical Sciences, Vol. 89, No. 1, January 2000. The other authors of the paper are Gregory S. Anderson, Michael G. Nichols, Jeremy A. Bartlett, William S. Mellon and Fritz Sieber.
3. I have read the above-identified application for patent and declare that I am the sole inventor of the subject matter claimed therein.


**BEST AVAILABLE COPY**

4. I conceived and directed the research described in the paper described in paragraph 2 above, and I was the lead investigator of the research.

5. The co-authors of the paper described in paragraph 2 above, other than myself, did not make an inventive contribution to the subject matter claimed in the application.


6. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: August 15, 2003

By:   
Guilherme L. Indig



A publication of the  
American  
Pharmaceutical  
Association



# Journal of Pharmaceutical Sciences

VOLUME 89, NUMBER 1  
January 2000

## MINI-REVIEW

### Drug/Cyclodextrin/Hydroxy Acid Multicomponent Systems. Properties and Pharmaceutical Applications

Enrico Redenti,\* Lajos Szente, and József Szejtli

1

## RESEARCH ARTICLES

### Water-Based Microsphere Delivery System for Proteins

Reena T. Patil\* and Tully J. Speaker

9

### A Priori Prediction of Tissue:Plasma Partition Coefficients of Drugs to Facilitate the Use of Physiologically-Based Pharmacokinetic Models in Drug Discovery

Patrick Poulin\* and Frank-Peter Theil

16

### Conjugation of Para-Nitrophenol by the Isolated Perfused Neonatal Sheep Liver

Paul J. Gow, Hany Ghabrial, Saard Treepongkaruna, Arthur Shulkes, Richard A. Smallwood, Denis J. Morgan, and Michael S. Ching\*

36

### Photopolymerized, Multilaminated Matrix Devices with Optimized Nonuniform Initial Concentration Profiles to Control Drug Release

Sanxiu Lu, W. Fred Ramirez, and Kristi S. Anseth\*

45

### Preparation and Characterization of pH-Responsive Polymeric Micelles for the Delivery of Photosensitizing Anticancer Drugs

J. Taillefer, M.-C. Jones, N. Brasseur, J. E. van Lier, and J.-C. Leroux\*

52

### Caco-2 versus Caco-2/HT29-MTX Co-cultured Cell Lines: Permeabilities Via Diffusion, Inside- and Outside-Directed Carrier-Mediated Transport

Constanze Hilgendorf, Hildegard Spahn-Langguth, Carl G. Regårdh, Elke Lipka, Gordon L. Amidon, and Peter Langguth\*

63

### Evaluation of Degradation Pathways for Plasmid DNA in Pharmaceutical Formulations via Accelerated Stability Studies

Robert K. Evans,\* Zheng Xu, Kathryn E. Bohannon, Bei Wang, Mark W. Bruner, and David B. Volkin

76

### Effect of Molecular Structure on the Performance of Triarylmethane Dyes as Therapeutic Agents for Photochemical Purging of Autologous Bone Marrow Grafts from Residual Tumor Cells

Guilherme L. Indig,\* Gregory S. Anderson, Michael G. Nichols, Jeremy A. Bartlett, William S. Mellon, and Fritz Sieber

88

(continued)

Journal of Pharmaceutical Sciences  
VOL. 89, NO. 1, JANUARY 2000

This Journal is Online

WILEY

InterScience®

www.interscience.wiley.com

Volume 89, Number 1 was mailed the week of January 31, 2000.

armaceuti  
nent and Di  
aw York, M  
rvice at (21

ould be for  
05 Third A  
Sales, Eur  
3affins Lan  
243 770 35

ript must b  
ed Copyright  
1.D., Depart  
University  
08.

d to the Cu  
Third Ave

nce to Jour  
iley & Son

ng: BIOS  
ISI, Inde  
Citation In  
urrent Co  
lex Medic

SO Z39.4

**Editor**

**William I. Higuchi**

Department of Pharmaceutics and Pharmaceutical Chemistry  
University of Utah  
421 Wakara Way, Room 315  
Salt Lake City, UT 84108

**Assistant Editor**

**Marilyn C. Masiker**

University of Utah, Salt Lake City, UT

**Associate Editors**

**David J. W. Grant**

University of Minnesota, Minneapolis, MN

**C. Russell Middaugh**

University of Kansas, Lawrence, KS

**Jashvant D. Unadkat**

University of Washington at Seattle, Seattle, WA

**Gaylen M. Zentner**

University of Utah, Salt Lake City, UT

**Associate Editor of Minireviews**

**Ronald T. Borchardt**

University of Kansas, Lawrence, KS

# Journal of Pharmaceutical Sciences



A publication of the  
**American  
Pharmaceutical  
Association**

PHARMACY LIBRARY

FEB 09 2000

7130 CHAMBERLIN HALL  
425 N. CHARLES ST. MADISON, WI 53706

**Editorial Advisory Board**

**Geogory E. Amidon**

Pharmacia & Upjohn, Inc.  
Kalamazoo, MI

**Bradley D. Anderson**

University of Utah  
Salt Lake City, UT

**Kenneth L. Audus**

The University of Kansas  
Lawrence, KS

**Bruce J. Aungst**

DuPont Pharmaceuticals  
Wilmington, DE

**Harry G. Brittain**

Center for Pharmaceutical  
Physics  
Milford, NJ

**Stephen R. Byrn**

Purdue University  
West Lafayette, IN

**John F. Carpenter**

University of Colorado Health  
Sciences Center  
Denver, CO

**Jens T. Carstensen**

University of Wisconsin  
Madison, WI

**William N. Charman**

Monash University  
Parkville, Australia

**Jeffrey L. Cleland**

Genentech, Inc.  
South San Francisco, CA

**Michael G. Cordingley**

Bio-Mega/Boehringer Ingelheim  
Quebec, Canada

**Daan J. A. Crommelin**

University of Utrecht  
Utrecht, The Netherlands

**Meindert Danhof**

Leiden University  
Leiden, The Netherlands

**George Famlni**

U.S. Army Edgewood RD&E  
Aberdeen Proving Ground, MD

**G. Richard Granneman**

Abbott Laboratories  
Abbott Park, IL

**James N. Herron**

University of Utah  
Salt Lake City, UT

**Norman F. H. Ho**

University of Utah  
Salt Lake City, UT

**William J. Jusko**

State University of New York  
at Buffalo  
Amherst, NY

**Gerald B. Kasting**

University of Cincinnati  
Cincinnati, OH

**William J. Lambert**

Elsai, Inc.  
Research Triangle Park, NC

**Robert S. Langer**

Massachusetts Institute of  
Technology  
Cambridge, MA

**Thomas M. Ludden**

GloboMax  
Hanover, MD

**Michael Mayersohn**

University of Arizona  
Tucson, AZ

**Kamal K. Midha**

University of Saskatchewan  
Saskatchewan, Canada

**Joyce J. Mordenti**

Axys Pharmaceuticals, Inc.  
South San Francisco, CA

**Kenneth R. Morris**

Purdue University  
West Lafayette, IN

**Marilyn E. Morris**

State University of New York  
at Buffalo  
Amherst, NY

**Tsuneji Nagai**

Hoshi University  
Tokyo, Japan

**Michael J. Pikal**

University of Connecticut  
Storrs, CT

**Gary M. Pollack**

University of North Carolina  
Chapel Hill, NC

**Michael F. Powell**

Sofinnova, Inc.  
San Francisco, CA

**Jim E. Riviere**

North Carolina State University  
Raleigh, NC

**Nair Rodriguez-Homedo**

The University of Michigan  
Ann Arbor, MI

**Ronald J. Sawchuk**

University of Minnesota  
Minneapolis, MN

**John T. Slaterry**

University of Washington  
Seattle, WA

**Janet G. Smith**

Valentis Inc.  
Burlingame, CA

**Marylee Z. Southard**

University of Kansas  
Lawrence, KS

**Valentino J. Stella**

University of Kansas  
Lawrence, KS

**Raj G. Suryanarayanan**

University of Minnesota  
Minneapolis, MN

**Yun K. Tam**

University of Alberta  
Edmonton, Canada

**Dhiren Thakker**

University of North Carolina  
Chapel Hill, NC

**John A. Thomson**

Vertex Pharmaceuticals, Inc.  
Cambridge, MA

**David B. Volkin**

Merck Research Laboratories  
West Point, PA

**Dominic J. Wells**

Imperial College of Medicine  
London, United Kingdom

**Peter York**

University of Bradford  
Bradford, United Kingdom

**Sumie Yoshioka**

National Institute of Health Sciences  
Tokyo, Japan

**David Young**

GloboMax LLC  
Hanover, MD

**George Zografi**

University of Wisconsin  
Madison, WI


[Home](#) / [Chemistry](#) / [Pharmaceutical and Medicinal Chemistry](#)

My Profile

[HOME](#)  
[ABOUT US](#)  
[CONTACT US](#)  
[HELP](#)

**Journal of Pharmaceutical Sciences****Volume 89, Issue 1, Pages 88 - 99**

Published Online: 7 Feb 2000

Copyright © 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association

☒ [Save Title to My Profile](#)   ☒ [Set E-Mail Alert](#)

Go to the homepage for this journal to access trials, sample copies, editorial and author information, news, and more.

☒ e-mail   ☐ print
**SEARCH** ☒ All Content☐ Publications[Advanced Search](#)[CrossRef / Google Search](#)[Acronym Finder](#)**SEARCH IN THIS TITLE**

Journal of Pharmaceutical Sciences

All Fields

**SEARCH BY CITATION**

Vol:   Issue:   Page:

**Recognized  
CAS Sci  
Spotlight  
source of  
most req  
journal a  
2004!**

Drs. Gopal Das, Naom and Stefan Matile are the authors of the most recent article of 2004

"Toward Catalytic Rigid Barrels: A Hexamer with Multiple Histidines"

[Read the article](#)**LATEST IMPACT FACTOR**

Journal of  
Pharmaceutical  
Sciences

Impact Factor increase

**2.180** \*

One of the top journals  
Medicinal Chemistry

\* ISI Journal Citation Report

☒ [Save Article to My Profile](#)   ☒ [Download Citation](#)
< [Previous Abstract](#) | [Next Abstract](#) >
[Abstract](#) | [References](#) | [Full Text: HTML, PDF \(299k\)](#) | [Related Articles](#) | [Citation Tracking](#)
**Research Article**

**Effect of molecular structure on the performance of triarylmethane dyes as therapeutic agents for photochemical purging of autologous bone marrow grafts from residual tumor cells**

Guilherme L. Indig<sup>1</sup>\*, Gregory S. Anderson<sup>2</sup>, Michael G. Nichols<sup>3</sup>, Jeremy A. Bartlett<sup>1</sup>, William S. Mellon<sup>1</sup>, Fritz Sieber<sup>2</sup>\*

<sup>1</sup>School of Pharmacy, Division of Pharmaceutical Sciences, University of Wisconsin, Madison, WI 53706<sup>2</sup>Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53223<sup>3</sup>Department of Applied and Engineering Physics, Cornell University, Ithaca, NY 14853email: Guilherme L. Indig ([gindig@facstaff.wisc.edu](mailto:gindig@facstaff.wisc.edu))

\*Correspondence to: Guilherme L. Indig, School of Pharmacy, Division of Pharmaceutical Sciences, University of Wisconsin, Madison, WI 53706

\*Correspondence to: Fritz Sieber, School of Pharmacy, Division of Pharmaceutical Sciences, University of Wisconsin, Madison, WI 53706

**Abstract**

Extensively conjugated cationic molecules with appropriate structural features naturally accumulate into the mitochondria of living cells, a phenomenon typically more prominent in tumor than in normal cells. Because a variety of tumor cells also retain pertinent cationic structures for longer periods of time compared with normal cells, mitochondrial targeting has been proposed as a selective therapeutic strategy of relevance for both chemotherapy and photochemotherapy of neoplastic diseases. Here we report that the triarylmethane dye crystal violet stains cell mitochondria with efficiency and selectivity, and is a promising candidate for photochemotherapy applications. Crystal violet exhibits pronounced phototoxicity toward L1210 leukemia cells but comparatively small toxic effects toward normal hematopoietic cells (murine granulocyte-macrophage progenitors, CFU-GM). On the basis of a comparative examination of chemical, photochemical, and phototoxic properties of crystal violet and other triarylmethane dyes, we have identified interdependencies between molecular structure, and selective phototoxicity toward tumor cells. These structure-activity relationships represent useful guidelines for the development of novel purging protocols to promote selective elimination of residual tumor cells from autologous bone marrow grafts with minimum toxicity to normal hematopoietic stem cells. © 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association *J Pharm Sci* 89: 88-99, 2000

Received: 23 September 1999; Revised: 23 November 1999; Accepted: 1 December 1999

**Digital Object Identifier (DOI)**10.1002/(SICI)1520-6017(200001)89:1<88::AID-JPS9>3.0.CO;2-K [About DOI](#)**Related Articles**

# TRANSWORLD RESEARCH NETWORK

37/661(2), Fort Post Office, Trivandrum 695 023, Kerala, India, Tel: +91-471-2452918, Fax: +91-471-2573051  
E-mail: ggcom@vsnl.com and admin@rsflash.com, Websites: <http://www.transworldresearch.com>  
and <http://www.researchsignpost.com>

February 13, 2004

## PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Guilherme L. INDIG

Docket No: 032026:0769

Serial No: 10/751, 302

FAX: 608.258.4258

Field: December 31, 2003

For: USE OF CRYSTAL VIOLET AS PHOTOCHEMOTHERAPEUTIC AGENT

### DECLARATION UNDER 37 C.F.R. § 1.132 OF S.G. PANDALAI

Mail Stop NON-FEE AMENDMENT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450


Sir:

I.S.G. Pandalai, state and declare that:

1. I am the Managing Editor of Transworld Research Network, publishers of the book, *Recent Research and Development in Pure & Applied Chemistry*, Vol.3(1999). An article entitled "Mechanisms of Action of Cationic Dyes in Photodynamic Therapy of Tumors," authored by Guilherme L. Indig appears on pages 9 through 19 of the book.
2. Although the book *Recent Research and Development in Pure & Applied Chemistry*, Vol.3 (1999) bears a publication year of 1999, it was actually first published in March of 2000.
3. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 13<sup>th</sup> February, 2004

By:

  
S.G. Pandalai

\*This declaration is submitted as per the request of Dr. Michelle Manning

FEDERAL SECURITY AGENCY  
Public Health Service

JEROME D. GOLDBERG  
EXAMINER  
GROUP ART UNIT 125



# AN INDEX OF TUMOR CHEMOTHERAPY

A tabulated compilation of data from the literature on  
clinical and experimental investigations

*"If no use is made of the labors of past ages, the world must  
remain always in the infancy of knowledge." Cicero*

JEROME D. GOLDBERG  
EXAMINER  
GROUP ART UNIT 125

REPORT

AUG 13 1951

By HELEN M. DYER, Biochemist  
National Cancer Institute  
National Institutes of Health

U S PATENT OFFICE

## NOTES TO TABULATED INDEX

Column 1 - No. - The numbers correspond to the numbers that follow the names of the agents in the alphabetical index.

Column 2 - Agent - No attempt has been made to use a consistent system of nomenclature for the chemical agents. Most frequently, the terminology employed in the original papers has been retained in the classified index. The alphabetical index of agents contains cross references between some of the names used in the classified index and the names of the agents according to the nomenclature of *Chemical Abstracts*.

*Optional names* for some of the agents are given in parentheses and are in italics.

*Trade names* of agents, when used, are found within parentheses in quotation marks.

Agents used for *supplementary treatment* are also included in parentheses but are not italicized. They are included in the alphabetical index.

To save space *chemical symbols* of chemical elements have been used for supplementary therapeutic agents when no special emphasis was made of the specific substances that contained the elements. Such symbols are not meant to indicate that element ions were administered as such. *Chemical formulas* of compounds have been used, where feasible, for simple inorganic supplementary agents.

*Gas treatment* refers to supplementary exposure of the tumor-bearing host to mixtures of carbon dioxide and oxygen.

## ABBREVIATIONS

ac. .... acute  
adcar. .... adenocarcinoma  
aden. .... adenoma  
ant. .... amount  
autol. .... autologous  
Bash. .... Bashford  
B. P. .... Brown-Pearce  
Buf. .... Buffalo  
bzp. .... benzpyrene  
can. .... cancer

Column 6 - Dosage - Dosage is expressed as *milligrams* except where otherwise indicated.

Column 7 - Number of Treatments - Numbers in parentheses following daily, weekly, etc. refer to total number of treatments.

Columns 9 and 10 - Effect Claimed - In these columns the numbers refer to the numbers of hosts showing the effect.

Column 9 - Effect on Tumor - The symbols and abbreviations for this column are as follows:

(±) .... growth of tumor inhibited      nec. .... necrosis in tumor  
(+) .... diminution in size of tumor      R ..... complete regression of tumor  
C ..... cure      stim. ... stimulation of tumor growth  
hemor. . hemorrhage in tumor      temp. ... temporary

Column 10 - Effect on Host - The symbols and abbreviations for this column are as follows:

(±) .... slight subjective improvement in host and/or diminution of pain      S>..... survival of treated animals for longer period of time than controls  
(+) .... significant subjective improvement      Tox. ... agent said to have toxic effects upon host

Column 11 - Reference Number - The reference number corresponds to the number found to the left of the reference in the bibliography.

car. .... carcinoma  
ca ..... cholanthrene  
chond. .... chondroma  
ch. .... chronic  
Cr. .... Crocker  
dbza ..... dibenzanthracene  
deriv. .... derivative  
dil. .... dilute  
div. .... divided  
dmaabz ..... dimethylaminoazobenzene



dmbza ..... 7,10-dimethyl-1,2-benzacridine  
 Ehr. .... Ehrlich  
 elect. .... electrically  
 epithel. .... epithelium  
 = ..... equals  
 esoph. .... esophagus  
 ext. .... estrogen  
 Flex. .... external  
 F. J. .... Flexner  
 Fuj. .... Flexner-Jobling  
 Gal. .... Fujiwara  
 gast. .... Galliera  
 gm ..... gastric  
 > ..... gram  
 H. P. .... greater than  
 heterol. .... Harding-Passey  
 Hodg. dis. .... heterologous  
 homol. .... Hodgkin's disease  
 hrly. .... homologous  
 HCl ..... hourly  
 ic ..... hydrochloride  
 id ..... intracardial  
 ig ..... intradermal  
 im ..... intragastric (by stomach tube)  
 ind. .... intramuscular  
 ind. (tar) ..... induced  
 inj. .... induced by tar, etc.  
 int. .... injection or injected  
 ip ..... interval  
 irr*ad* ..... intraperitoneal  
 it ..... irradiation  
 iv ..... intratumoral  
 iv(sc) ..... intravenous  
 Jen. .... intravenously, occasionally subcutaneous  
 K ..... Jensen  
 < ..... kilogram  
 L.D. .... less than  
 leuk. .... lethal dose  
 leukos. .... leukemia  
 loc. .... leukosis  
 lym. .... local application  
 lymgran. .... lymphatic  
 lymph. .... lymphogranuloma  
           ..... lymphoma

lym*sa*r. .... lymphosarcoma  
 ma. .... mammary  
 mc ..... millicurie  
 mca ..... methylcholanthrene  
 Mch. u ..... Mache unit  
 mel. .... melanoma  
 melsar. .... melanosarcoma  
 metas. .... metastasis or metastasizing  
 m. fung. .... mycosis fungoides  
 mg ..... milligram  
 min. .... minim  
 misc. .... miscellaneous  
 ml ..... milliliter  
 m.u. .... mouse unit  
 mult. .... multiple  
 mye. .... myelogenous  
 myel. .... myeloma  
 osteosar. .... osteosarcoma  
 ovar. .... ovarian  
 pap. .... papilloma  
 Phila. .... Philadelphia  
 † ..... with or without  
 polycy. .... polycythemia vera  
 prep. .... preparation or prepared  
 Put. .... Putnoky  
 r ..... Röntgen  
 sar. .... sarcoma  
 sat. .... saturated solution  
 sc ..... subcutaneous  
 sol. .... solution  
 sp. .... spontaneous  
 suppl. .... supplementary  
 surg. .... surgery  
 Teut. .... Teutschländer  
 T.D. .... tolerated dose  
 tr. .... transplant, transplantation or transplanted  
 tr. tar-ind. .... transplanted tar-induced, etc.  
 treat. .... treatment  
 vag. .... vaginal  
 tum. .... tumor  
 u ..... unit  
 ulc. .... ulcerated  
 uter. .... uterus, uterine  
 u.v. .... ultraviolet  
 Wal. .... Walker

## PUNCTUATION

Colons have been used to avoid repetition of words where several types of tumors have been employed in a test. Thus, *Tr.: car., sar.* indicates *transplanted carcinoma* and *transplanted sarcoma*. The same is true, when for other reasons, colons or semicolons are used between *car.* and *sar.* following the *Tr.:* Except where man is the host (in which case all the tumors are spontaneous) *tr.:*, when followed by a colon carries over until *ind.* or *sp.* appear. The same is true for *ind.:* or *sp.:*

Commas have been used to separate varied experimental conditions in a single test (as different types of tumors and/or kinds of hosts, dosage, routes of administration) where no significant difference was reported in the therapeutic effect of the agent relating specifically to the varied conditions.

Semicolons have been used to relate varied experimental conditions in different columns where the conditions were considered to be of significance.

*Example 1: Under agent No. 1 in the table both spontaneous and transplanted carcinomas of the mouse showed an inhibiting effect of the agent. When administered in the drinking water diminution (+) in the size of tumors and regressions, R, were reported; when administered subcutaneously only an inhibiting effect (+) was reported.*

*Example 2: Under agent No. 13 no distinction was made in dosage, number of treatments or routes of administration, but the effect on the tumors was reported as negative for the transplanted carcinoma, negative for the transplanted sarcoma, positive for the induced-tar papilloma and negative for the induced-tar carcinoma.*

*Example 3: Under agent No. 25 the therapeutic effect was the same for spontaneous or transplanted carcinomas of the mouse, for spontaneous carcinomas of the dog and for transplanted sarcomas of the rat, but the agent was more effective (+) when administered intravenously than when given subcutaneously (±).*

Sometimes a semicolon is found in the supplementary treatment (within parentheses) under agent, when this experimental condition has been shown to have a significant influence on the effect of therapy.

*Example 4: Colloidal lead (without; with irradiation), and in the Effect Claimed columns (-); (+) indicates that colloidal lead was found to be ineffective when administered alone but beneficial when given with irradiation.*

NO.	AGENT	TYPE OF TUMOR	HOST		THERAPY				REFERENCE	
			SPECIES	NUMBER	DOSAGE	NUMBER OF TREATMENTS	ROUTE	EFFECT CLAIMED TUMOR (Objective) HOST (Subjective)	NUMBER	DATE
3475	Trypan red (C.I. No. 438:disazo)	Car. breast	Man	1	500;.5%	Repeated	Oral; sc	(-); (+)	952	1905
3476	----- (and cocaine)	Can.; gastric; lym. adcar.	"	2; 1	500	"	sc	(?); (+)	1728	1906
3477	"	Sp.ma.car.	Mouse, Marsh	3	2	16	Iv, sc	(-)	1306	1927
3478	"	Ind. (tar)car.	Mouse	20-50	4	Weekly	Iv	(-)	659	1931
3479	"	Tr. lym.sar.	Mouse, C3H	4	1	10-16	sc	(-)	2140	1946
3480	Unclassified azo dyes (17 samples)	Tr.sar.	Mouse	25 each	.15-.4%	14 days	In food	(-)	1199	1947
3481	Vital new red ("Grübler")	Tr.car.206	"	19	.5%	8	sc	(-); stim.	1245	1931
3482	Vital red (C.I. No. 456:disazo)	Sp.ma.car.	Mouse, Marsh	6	2	14-19	Iv, sc	(-)	1306	1927
(2). OTHER MISCELLANEOUS CLASSES: ANTHRAQUINONE; NITRO; NITROSO; QUINOLINE; THIAZOLE DYES.										
3483	Ahco 26-47 (1,4-diaminoanthraquinone)	Tr.; car.; sar.	Mouse	25; 25	25%	16 days	In food	(+)	1199	1947
3484	Alizarin	Sp.ma.car.	Mouse, Marsh	3	.05 ml sat	53	sc	(-)	1306	1927
3485	----- red S (C.I. No. 1094:anthraquinone dye)	Tr.; car.; sar.	Mouse	3	1	50	Iv, sc	(-)	1306	1927
3486	Aniline trichloratum (As-free)	Tr.; car.; sar.	Man	4; 1	1-4 gm	Repeated	It	(-); (+); (+)	2059, 2060	1891, 192
3487	Anthraquinone dyes (61 samples)	Tr.sar.	Mouse	25 each	.15-.4%	14 days	In food	(-)	1199	1947
3488	----- (vat, 57 samples)	"	"	25 each	.15-.4%	14 days	"	(-)	1199	1947
3489	-----, 1,4,5,8-tetramine-1AQD-24(1)	Tr.; car.; sar.	"	25; 25	.15-.4%	14 days	"	(+); (+)	1199	1947
3490	Isoquinoline red	Tr.car.	"	13	---	---	---	(+), 6C	996	1931
3491	Martin's yellow (2,4-dinitro-1-naphthol, salt of-)	"	"	5	---	---	---	(-)	1306	1927
3492	Naphthol green B (C.I. No. 5:nitroso dye)	Sp.car.	Mouse, Marsh	3	8	33	Iv, sc	(-)	640	1930
3493	"	Tr.car.	Mouse	---	10	Repeated	sc	(+), 2R	1795	1926
3494	Naphthol yellow (C.I. No. 9:nitroso dye)	Sp.ma.car.	Mouse, Inbred	25 each	.15-.4%	14 days	Iv, sc	(-)	1199	1947
3495	Nitro dyes (4 samples)	Tr.sar.	Mouse	25 each	.15-.4%	14 days	In food	(-)	1199	1947
3496	Nitroso dyes (2 samples)	"	"	25 each	.2ml sat.	46	sc	(-)	1306	1927
3497	Primuline (C.I. No. 812:thiazole dye)	Tr.sar.	Mouse, Marsh	25 each	.15-.4%	14 days	In food	(-)	1199	1947
3498	Quinoline dyes (5 samples)	Sp.ma.car.	Mouse, Marsh	25 each	.15-.4%	14 days	Iv, sc	(-)	1306	1927
3499	Quinoline yellow (C.I. No. 801)	Tr.sar.	Mouse	6	20	33-67	Iv, sc	(-)	1199	1947
3500	"	Tr.sar.	Rat.	12-15	25	1	Ip	(-)	76	1942
3501	Soledon blue (anthraquinone dye)	Tr. Wal. car. 256	Mouse	25 each	.15-.4%	14 days	In food	(-)	1199	1947
3502	Sulfur dyes (11 samples)	Tr.sar.	Mouse, Marsh	3	60	45	Iv, sc	(-)	1306	1927
3503	Tartrazine (Buffalo-yellow; C.I. No. 690: pyrazolon dye)	Sp.ma.car.	Mouse	25 each	.15-.4%	14 days	Iv, sc	(-)	1199	1947
3504	Thiazole dyes (10 samples)	Tr.sar.	Mouse	25 each	.15-.4%	14 days	Iv, sc	(-)	1199	1947
3505	Thioaniline dye	Tr. Buf. sar.	Rat	---	---	---	---	Tox.	2116	1916
(3). TRIPHENYL-METHANE DYES										
3506	Alkali blue (C.I. No. 710: similar or identical to isamine blue)	Sp.ma.car.	Mouse, Marsh	3	.4 ml sat.	27	"	(-)	1306	1927
3507	Aniline blue	Tr. car. 2146	Mouse, MRC	5	.3%	Ad lib	In food	(+)	1630	1948
3508	Auramine O (C.I. No. 655: pyoktanin yellow)	Sp.ma.car.	Mouse, Marsh	3	.4	26	Iv, sc	(-)	1306	1927
3509	Blorubin (C.I. No. 678: new fuchsin, iso-rubin)	"	"	3	.2	39	"	(-)	1306	1927
3510	Brilliant dianiline blue 6G (C.I. No. 710: isamine blue 6B, 8B)	Ind. (tar)car.	Mouse	30-50	10	Weekly	Iv	(-)	659	1931
3511	Cotton blue (C.I. No. 707: Poirrier's blue)	Sp.ma.car.	Mouse, Marsh	3	4	14	sc	(-)	1306	1927
3512	Crystal violet (C.I. No. 682: gentian violet, methyl violet)	Car.; sar.	Man	6; 4	2000-3000	21-125	It	(+); (+)	2060	1892
3513	Crystal violet	Sp.ma.car.	Mouse, Marsh	3	.5	25	Iv, sc	(-)	1306	1927
3514	----- (with gas treat.)	Tr. misc. tum.	Mouse	---	.2-.3ml	Repeated	sc	Tox.	640	1930

NO.	AGENT	TYPE OF TUMOR	HOST		THERAPY					REFERENCE	
					SPECIES	NUMBER	DOSAGE	NUMBER OF TREATMENTS	ROUTE	EFFECT CLAIMED	
										TUMOR (Objective)	HOST (Subjective)
3515	Crystal violet	Tr.car.2146	Mouse, MRC	5	.3%	Ad lib	In food	(+)	Tox.	1630	1948
3516	----- (B.P.C.)	Tr.car.2146	" "	5	.3%	" "	" "	(+)	"	1630	1948
3517	Dahlia (C.I.No.679; Hofmann's violet)	Sp.ma.car.	Mouse	6	.2-1 ml sat.	9-22	iv, sc	(-)	"	1306	1927
3518	Erioglaucine	" "	" "	3	20	44	" "	(-)	"	1306	1927
3519	Ethyl violet (C.I.No.682)	" "	" "	3	.33	14	" "	(-)	"	1306	1927
3520	----- (hexaethyltrisaminotriphenyl-carbinol anhydride)	Tr.:car.;sar.	" "	25; 25	.2%	14 days	In food	(+); (+)	Tox.	1199	1947
3521	" "	Tr.:car.2146; Cr.sar.180	Mouse, MRC	15; 5	.3%; .5%	Ad lib	" "	(+); (-)	"	1630	1948
3522	Fuchsin (amaranth, dahlia etc.)	Misc.car.	Man	4	---	Repeated	Local	(+)	(+)	543	1890-91
3523	" "	Epithel.	" "	1	---	"	"	(+)	(+)	1343	1891
3524	" "	Sp.ma.car.	Mouse, inbred	3	.3-.4	9-10	iv, sc	(-)	"	1795	1926
3525	----- (acid: rubine S)	" "	" "	1	17-34	26	" "	(-)	"	1795	1926
3526	----- (neutral)	" "	" "	1	.5	19	sc	(-)	"	1795	1926
3527	----- (acid)	Ind.(tar)car.	Mouse	20-50	40	Weekly	iv	(-)	"	659	1931
3528	" "	Tr.Tsunoda sar.	Rat	---	---	Repeated	"	(-)	"	1776	1931
3529	----- (basic: $\pm$ heparin)	Tr.car.2146	Mouse, MRC	5; 5; 5	1%; .5-1 ml; .3%	1; daily; ad lib	With tr.; sc; in food	(+); (-); (-)	"	1630	1948
3530	Gentian violet (see also crystal violet)	Sp.ma.car.	Mouse, inbred	3	.5-4	7-13	iv, sc	(-)	"	1795	1926
3531	Glacier blue	Tr.car.2146	Mouse, MRC	5	.3%	Ad lib	In food	(-)	"	1630	1948
3532	Hofmann's violet	" "	" "	5	.3%	"	" "	(-)	"	1630	1948
3533	Ismine blue (C.I.No.710 is 68 or 88; with .075% 15 gm neosalvarsan)	Misc.car.	Man	2; 2	5-20 ml	Repeated	iv	(+); (+)	"	1662	1923
3534	----- (8588, in glycol or olive oil)	Car.; tr.tum.	Man; mouse	---	500; 10	"	ip	(+); (+)	"	1663	1924
3535	" "	Sp.ma.car.	Mouse, inbred	2	19-41	"	iv, sc	(-)	"	1664	1925
3536	" "	" "	Mouse, Marsh	1	2	31	" "	(-)	"	1795	1925
3537	" "	Car., rectal	Man	1	10-20 ml	2	iv	(-)	"	1306	1927
3538	----- (sometimes other medication)	Misc.car.	" "	40	25-160	24(2-3ser)	" "	(+); (-)	Tox.	88	1928
3539	" "	" "	" "	33	5-20 ml	24(2-3ser)	" "	5(1), 8(-)	(+)	181, 184	1928
3540	----- (also eosin and PbS)	Car., skin	" "	8	5-20 ml	24(2-3ser)	" "	(+)	(+)	181, 184	1928
3541	----- (containing 2% glycerine)	Tr.:sar.; car., sar.	Rabbit; rat	5	5-20 ml	Daily-30 day	" "	(+)	"	1007	1928
3542	" "	Car.: breast; gast.	Man	1; 1	1%	Daily Int.	Int.	(-)	"	1038	1928
3543	" "	Misc.car.	" "	200	5-15 ml .5%	Daily- weekly	iv	(+); (+)	"	1666	1929
3544	----- (8789T; $\pm$ irradi.; $\pm$ PbI <sub>2</sub> in sodium lactate)	" "	" "	8	20-80	Daily, 1 day	" "	(+), (-)	"	182, 183	1930
3545	----- (followed by irradi.)	Epithel.	" "	2	25-100	10-12/ser.	" "	(+)	"	407	1930
3546	----- (68, alone; stabilized by glycerine)	Tr.car.	Mouse	---	1-3	5 day Int.	" "	(+)	"	533	1930
3547	----- (B731, pure)	" "	" "	---	2-3	5 day Int.	" "	(+)	"	640	1930
3548	----- (with gas treat.)	" "	" "	---	1-3	5 day Int.	" "	(+)	"	640	1930
3549	----- (with saccharated Fe <sub>2</sub> O <sub>3</sub> or FeSO <sub>4</sub> (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> )	" "	" "	---	2-3	5 day Int.	" "	(+)	"	640	1930
3550	----- (with K <sub>2</sub> Fe(CN) <sub>6</sub> and gas treat.)	" "	" "	---	1-3	5 day Int.	" "	(-)	"	640	1930
3551	----- (in 2% serum albumin)	Tr.:F.J.J.car.;sar.	Rat; mouse	109	30-100 ml	Repeated	iv	(-)	Tox.	640	1930
3552	" "	Misc.car.	Man	30-50	5	Weekly	" "	(-)	"	640	1930
3553	" "	Ind.(tar)car.	Mouse	>1	40-160	2-3 day Int.	" "	(+), 13(-)	(+)	2190, 2192	1930
3554	----- (medicinal, with Bi)	Car., epithel.	Man	---	---	---	" "	(-)	"	659	1931
3555	----- (followed by irradi.)	" "	" "	---	---	---	" "	(+)	"	1088	1931

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**